Phase 1 Radioimmunotherapy Study with Lutetium 177–labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Phase 1 Radioimmunotherapy Study with Lutetium 177–labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

Published:2013-09 Issue:3 Volume:64 Page:478-485
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Stillebroer Alexander B.,Boerman Otto C.,Desar Ingrid M.E.,Boers-Sonderen Marije J.,van Herpen Carla M.L.,Langenhuijsen Johannes F.,Smith-Jones Peter M.,Oosterwijk Egbert,Oyen Wim J.G.,Mulders Peter F.A.

Publisher

Elsevier BV

Subject

Urology

Reference29 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Treatment of metastatic renal cell carcinoma;Reeves;Cancer Chemother Pharmacol,2009

3. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007

4. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

5. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250;Steffens;J Clin Oncol,1997

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma;Frontiers in Oncology;2024-09-10

2. Current clinical application of lutetium‑177 in solid tumors (Review);Experimental and Therapeutic Medicine;2024-03-26

3. Preclinical Characterization of DPI-4452: A⁶⁸Ga/¹⁷⁷Lu Theranostic Ligand for Carbonic Anhydrase IX;Journal of Nuclear Medicine;2024-03-21

4. Towards Effective CAIX-targeted Radionuclide and Checkpoint Inhibition Combination Therapy for Advanced Clear Cell Renal Cell Carcinoma;2024-02-21

5. Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma;Theranostics;2024